AOD-9604 + CJC-1295 + Ipamorelin 12mg Blend
A 12 mg multi-pathway research blend uniting lipolytic fragment AOD-9604 with CJC-1295 and Ipamorelin for amplified GH axis signaling.
Mechanism
This blend stimulates pituitary somatotrophs via dual GHRH and GHS-R pathways while concurrently triggering localized adipocyte lipolysis through an isolated C-terminal hGH sequence.
Dosing
Standard laboratory protocols initiate daily administration at 400 mcg of total blend drawn from the reconstituted solution.
Reconstitution
Reconstituting the 12 mg vial with 3.0 mL of bacteriostatic water yields a stock concentration of 4 mg/mL (4,000 mcg/mL).
Storage
Store unmixed lyophilized vials at -20°C and maintain reconstituted solutions refrigerated between 2°C and 8°C protected from light.
Mix & measure AOD-9604 + CJC-1295 + Ipamorelin 12mg Blend
Pre-filled with this protocol's recommended BAC water and documented starting dose — edit any field to run your own numbers.
Mix & measure AOD-9604 + CJC-1295 + Ipamorelin 12mg Blend
Vial strength → BAC water → target dose
Total doses in vial: 30.0
U-100 syringe: 100 units = 1 mL
Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Advanced calculator →
Dosing Chart
| Phase / Day(s) | Dose & Frequency | Volume (U-100 units / mL) |
|---|---|---|
| Weeks 1–4 | 400 mcg (0.4 mg) (1× daily) | 10 units (0.10 mL) |
| Weeks 5–8 | 800 mcg (0.8 mg) (1× daily) | 20 units (0.20 mL) |
| Weeks 9–12 | 1,200 mcg (1.2 mg) (1× daily) | 30 units (0.30 mL) |
Reconstitution Steps
- 1
Draw 3.0 mL of bacteriostatic water into a sterile syringe.
- 2
Release it slowly down the vial’s inner wall to limit foaming.
- 3
Swirl or roll gently until fully dissolved — don’t shake.
- 4
Label with the date and concentration, then refrigerate at 2–8 °C (35.6–46.4 °F), shielded from light.
Supplies Needed
Peptide Vial
AOD-9604 + CJC-1295 + Ipamorelin, 12 mg combined blend vial (planned across the study cycle)
Insulin Syringes (U-100)
1 mL U-100 sterile syringes for daily experimental administration
Bacteriostatic Water
3.0 mL per 12 mg vial for dilution and reconstitution
Alcohol Swabs
Sanitization of the vial septum and intended injection area prior to each draw
Why researchers study it
Fat metabolism & lipolysis
GH & IGF-1 support
Body composition
Recovery & sleep
These describe what is being studied, not proven benefits, approved uses, or promised results.
Overview
The AOD-9604 + CJC-1295 + Ipamorelin formulation combines three distinct synthetic peptides into a single 12 mg vial (proportioned as 6 mg AOD-9604, 3 mg CJC-1295, and 3 mg Ipamorelin). This multi-target design is structured for investigational protocols assessing synergistic endocrine modulation, specifically seeking to evaluate metabolic remodeling and somatotropic axis stimulation in tandem. By uniting a truncated fragment of human growth hormone with both a GHRH analog and a ghrelin receptor agonist, the blend allows laboratory models to examine localized lipolytic pathways alongside endogenous pituitary growth hormone secretion. Because the components are co-lyophilized within a shared matrix, dosing assessments reflect the combined administration of all three compounds rather than isolated singular effects.
References
- 1.Teichman et al., Journal of Clinical Endocrinology & Metabolism, 2006 — CJC-1295 (a GHRH analog) prolongs and elevates GH and IGF-1 in healthy adults
- 2.Raun et al., European Journal of Endocrinology, 1998 — Ipamorelin, a selective ghrelin/GHS-R agonist and GH secretagogue
Supplies Needed
Suggested supplier
Research use only. Listing a supplier is not an endorsement of any protocol on this site, and nothing sold there is approved for human use.